A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Summary

The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-186 (MVC-101). Participants may receive treatment throughout the study for a maximum of 13 months and will be followed up at 30 days and 90 days and then every 12 weeks for up to 48 weeks after the last treatment.

Timeline

Start

2021-03-08

Primary completion

2025-06-17

Completion

2025-06-17

Drugs

Indications